| Code | CSB-RA004844MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to the reference antibody described in US20090110686A1, specifically targeting CCR5 (C-C chemokine receptor type 5). CCR5 functions as a critical chemokine receptor expressed primarily on T cells, macrophages, and dendritic cells, mediating cellular migration and immune responses through interaction with chemokines including CCL3, CCL4, and CCL5. This receptor plays a pivotal role in HIV-1 pathogenesis as the principal co-receptor for viral entry into host cells, and has been implicated in various inflammatory conditions, autoimmune diseases, and certain cancers where it influences tumor microenvironment dynamics and metastatic potential.
The reference antibody represents a well-characterized anti-CCR5 therapeutic candidate with demonstrated blocking activity against chemokine binding and HIV entry. This biosimilar provides researchers with a valuable tool for investigating CCR5-mediated signaling pathways, studying HIV infection mechanisms, exploring immune cell trafficking, and evaluating CCR5 as a therapeutic target in oncology and inflammatory disease models. The antibody enables detailed examination of CCR5 expression patterns and functional roles across diverse experimental systems.
There are currently no reviews for this product.